Dr. William Nicholson
Claim this profileEmory University Hospital
Studies Coronary Artery Disease
Studies Myocardial Ischemia
9 reported clinical trials
10 drugs studied
Affiliated Hospitals
Clinical Trials William Nicholson is currently running
PCI vs Medical Management
for Aortic Stenosis
Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while others follow an alternative strategy of medical management. The potential benefits and optimal timing of PCI in these patients are unknown. As TAVR expands to lower risk patients, and potentially becomes the preferred therapy for the majority of patients with severe aortic stenosis, the optimal management of concomitant coronary artery disease will be of increasing importance. The COMPLETE TAVR study will determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia-driven Revascularization or Hospitalization for Unstable Angina or Heart Failure. The study will be a randomized, multicenter, open-label trial with blinded adjudication of outcomes. Patients will be screened and consented for elective transfemoral TAVR and randomized within 96 hours of successful balloon expandable TAVR. Complete Revascularization: Staged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions in vessels that are at least 2.5 mm in diameter and that are amenable to treatment with PCI and have a ≥70% visual angiographic diameter stenosis. Staged PCI can occur any time from 1 to 45 days post successful transfemoral TAVR. Vs. Medical Therapy Alone: No further revascularization of coronary artery lesions. All patients, regardless of randomized treatment allocation, will receive guideline-directed medical therapy consisting of risk factor modification and use of evidence-based therapies. The COMPLETE TAVR study will help address the current lack of evidence in this area. It will likely impact both the global delivery of health care and the management and clinical outcomes of all patients undergoing TAVR with concomitant CAD.
Recruiting1 award N/A4 criteria
Impella-Supported PCI
for Coronary Heart Disease
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health after a heart procedure compared to the current standard of care.
Recruiting1 award N/A5 criteria
More about William Nicholson
Clinical Trial Related3 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments William Nicholson has experience with
- Impella®-Supported PCI
- Neovasc Reducer System
- Implantation Procedure With No Device Implanted
- Percutaneous Coronary Intervention (PCI)
- VasoStar
- NovaCross
Breakdown of trials William Nicholson has run
Coronary Artery Disease
Myocardial Ischemia
Coronary Heart Disease
Aortic Valve Stenosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does William Nicholson specialize in?
William Nicholson focuses on Coronary Artery Disease and Myocardial Ischemia. In particular, much of their work with Coronary Artery Disease has involved treating patients, or patients who are undergoing treatment.
Is William Nicholson currently recruiting for clinical trials?
Yes, William Nicholson is currently recruiting for 3 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that William Nicholson has studied deeply?
Yes, William Nicholson has studied treatments such as Impella®-Supported PCI, Neovasc Reducer System, Implantation procedure with no device implanted.
What is the best way to schedule an appointment with William Nicholson?
Apply for one of the trials that William Nicholson is conducting.
What is the office address of William Nicholson?
The office of William Nicholson is located at: Emory University Hospital, Atlanta, Georgia 30322 United States. This is the address for their practice at the Emory University Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.